| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 10MM | +17% |
| Operating Income | -14.6MM | -7% |
| Operating Expenses | 24.6MM | +1% |
| Net Income | -11.7MM | -11% |
| R&D | 19.1MM | -0% |
| G&A | 5.4MM | +9% |
| Interest Expense | 0 | -100% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The biotech just added another potential growth driver to its pipeline.
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio. The broader biotech industry is brimming with significant potential, making incredible advancements. Innovations span fields like drug discovery, gene editing, regenerative medicine and diagnostics. These technologies hold promise to treat a wide
Vertex just laid claim to an asset that might be very valuable.
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
AstraZeneca, Alpine Immune Sciences and more in the latest Market Talks covering the Health Care sector.
Earnings at CarMax miss analysts’ estimates, Alpine Immune Sciences is being acquired by Vertex Pharmaceuticals for $4.9 billion in cash, Robinhood stock is downgraded, and Nike receives an upgrade.
Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine's stock at $65 a share, which is a nearly 67% premium from the stock's close on Tuesday. Yahoo Finance Anchors Josh Lipton and Julie Hyman discuss the trend of "pipeline in a product" deals. For more expert insight and the latest market action, click here to watch this full episode of Market Domination...
Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal.
**Alpine Immune Sciences (ALPN)**: Biotech company **Vertex Pharmaceuticals (VRTX)** agreed to buy Alpine for $4.9 billion, to bolster its kidney-disease portfolio. The target company's shares soared over 36%, extending Wednesday's gains.